These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 2415645)

  • 1. Immunologic and clinical responses to varicella-zoster virus-specific transfer factor following marrow transplantation.
    Bowden RA; Siegel MS; Steele RW; Day LM; Meyers JD
    J Infect Dis; 1985 Dec; 152(6):1324-7. PubMed ID: 2415645
    [No Abstract]   [Full Text] [Related]  

  • 2. Activation of lymphocytes by varicella-zoster virus (VZV): expression of interleukin-2 receptors on lymphocytes cultured with VZV antigen.
    Ito M; Nakano T; Kamiya T; Kitamura K; Komada Y; Ihara T; Kamiya H; Sakurai M
    J Infect Dis; 1992 Jan; 165(1):158-61. PubMed ID: 1309371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologic and immunologic characterization of the soluble skin-test antigen of varicella-zoster virus.
    Shiraki K; Yamanishi K; Takahashi M
    J Infect Dis; 1984 Apr; 149(4):501-4. PubMed ID: 6327833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell-mediated immunity to varicella-zoster virus: in vitro lymphocyte responses.
    Jordan GW; Merigan TC
    J Infect Dis; 1974 Nov; 130(5):495-501. PubMed ID: 4370611
    [No Abstract]   [Full Text] [Related]  

  • 5. Determination of immunity to varicella-zoster virus by means of an intradermal skin test.
    LaRussa P; Steinberg SP; Seeman MD; Gershon AA
    J Infect Dis; 1985 Nov; 152(5):869-75. PubMed ID: 2995511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transfer factor for the prevention of varicella-zoster infection in childhood leukemia.
    Steele RW; Myers MG; Vincent MM
    N Engl J Med; 1980 Aug; 303(7):355-9. PubMed ID: 6248780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transfer factor and cellular reactivity to varicella-zoster antigen in childhood leukemia.
    Steele RW
    Cell Immunol; 1980 Mar; 50(2):282-9. PubMed ID: 6244113
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical and subclinical reactivations of varicella-zoster virus in immunocompromised patients.
    Ljungman P; Lönnqvist B; Gahrton G; Ringdén O; Sundqvist VA; Wahren B
    J Infect Dis; 1986 May; 153(5):840-7. PubMed ID: 3009635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody responses to early antigens of varicella-zoster virus (VZV) during varicella and zoster.
    Namazue J; Kato T; Yamanishi K; Takahashi M; Asano Y; Muraki R
    Biken J; 1986 Dec; 29(3-4):91-7. PubMed ID: 3039973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subclinical varicella-zoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation.
    Wilson A; Sharp M; Koropchak CM; Ting SF; Arvin AM
    J Infect Dis; 1992 Jan; 165(1):119-26. PubMed ID: 1309369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human T cells recognize multiple epitopes of an immediate early/tegument protein (IE62) and glycoprotein I of varicella zoster virus.
    Bergen RE; Sharp M; Sanchez A; Judd AK; Arvin AM
    Viral Immunol; 1991; 4(3):151-66. PubMed ID: 1725699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody to early antigens of varicella-zoster virus during varicella and zoster.
    Gerna G; Cereda PM; Cattaneo E; Achilli G; Gerna MT
    J Infect Dis; 1979 Jul; 140(1):33-41. PubMed ID: 88490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokine production in varicella-zoster virus-stimulated cultures of human blood lymphocytes.
    Hayward AR; Cosyns M; Jones M; Levin MJ; Villanueba E; Weinberg A; Chan CY
    J Infect Dis; 1998 Nov; 178 Suppl 1():S95-8. PubMed ID: 9852984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delayed hypersensitivity skin test to detect susceptibility to varicella and zoster.
    Berger R; Luescher D; Just M; D'Hondt E; Bogaert H
    Postgrad Med J; 1985; 61 Suppl 4():137-41. PubMed ID: 3014471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Congenital varicella-zoster virus infection and the failure to establish virus-specific cell-mediated immunity.
    Grose C
    Mol Biol Med; 1989 Oct; 6(5):453-62. PubMed ID: 2560525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ability of yeast Ty-VLPs (virus-like particles) containing varicella-zoster virus (VZV)gE and assembly protein fragments to induce in vitro proliferation of human lymphocytes from VZV immune patients.
    Welsh MD; Harper DR; Garcia-Valcarcel M; Fowler WJ; Aitken C; Jeffries DJ; Layton GT
    J Med Virol; 1999 Sep; 59(1):78-83. PubMed ID: 10440812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular and humoral immunity to varicella zoster virus glycoproteins in immune and susceptible human subjects.
    Giller RH; Winistorfer S; Grose C
    J Infect Dis; 1989 Dec; 160(6):919-28. PubMed ID: 2555419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of varicella-zoster virus-infected cell proteins that elicit antibody production during primary varicella using the immune transfer method.
    Palumbo PE; Arvin AM; Koropchak CM; Wittek AE
    J Gen Virol; 1984 Dec; 65 ( Pt 12)():2141-7. PubMed ID: 6096492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunology of the varicella-zoster virus glycoproteins.
    Grose C; Litwin V
    J Infect Dis; 1988 May; 157(5):877-81. PubMed ID: 2834465
    [No Abstract]   [Full Text] [Related]  

  • 20. [Is vaccination against varicella efficacious and how long does the protection last?].
    Ołdak E
    Med Wieku Rozwoj; 2013; 17(4):341-6. PubMed ID: 24519777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.